T-cell-engaging bispecific antibodies (BsAbs) simultaneously bind to antigens on tumour
cells and CD3 subunits on T cells. This simultaneous binding results in the recruitment of T …

Progress in the research and therapy of adult acute lymphoblastic leukemia (ALL) is
accelerating. This analysis summarizes the data derived from the clinical trials conducted at …

Background Ponatinib and blinatumomab are effective therapies in patients with
Philadelphia chromosome-positive (Ph-positive) acute lymphoblastic leukaemia, and their …

The combination of ponatinib, a third‐generation BCR:: ABL1 tyrosine kinase inhibitor, with
hyper‐CVAD chemotherapy resulted in high rates of complete molecular remissions and …

There are five fibroblast growth factor receptors (FGFRs), namely, FGFR1–FGFR5. When
FGFR binds to its ligand, namely, fibroblast growth factor (FGF), it dimerizes and …

Simple Summary Bispecific T-cell engagers (BiTEs) and bispecific antibodies (BiAbs) have
emerged as novel therapeutic modalities in the treatment of advanced hematological …

Importance In newly diagnosed Philadelphia chromosome–positive (Ph+) acute
lymphoblastic leukemia (ALL), disease progression due to acquired resistance to first-or …

目前造血干细胞移植已成为急性白血病治疗中不可或缺的组成部分. 虽然过去20
年来靶向治疗及免疫治疗迅速发展, 提高了急性白血病的疗效, 但造血干细胞移植的治疗地位 …

The management of Philadelphia chromosome-positive (Ph-positive) acute lymphoblastic
leukemia (ALL) has witnessed major progress over the past two decades. Initially, the …

Clinical trials frequently include multiple end points that mature at different times. The initial
report, typically based on the primary end point, may be published when key planned co …